Vin 37 Solaris Vaccines announced it raised $35,000 in an initial filing from an offering of $500,000

Company

Location

About

Addressing the significant threat to global health posed by current and future pathogens is a critical unmet need laid bare by the ongoing pandemic. Both traditional and emerging approaches to creating vaccines have limitations, and new options are urgently required. Solaris is applying a technology previously used for inactivating pathogens in the blood supply to rapidly produce safe and effective vaccines against viruses, bacteria and parasites under the trade name SolaVAX™.